In addition, the full CSF biomarker panel was available only for a subgroup of PD patients and controls, did not include the phosphorylated-tau-217, which is a very sensitive index of AD-related tau pathology[37, 38], or a quantitative α-syn seeding amplification assay (SAA), which would be critical for the sensitive in vivo quantification of Lewy body pathology [39]. The gene discussed is MAPT; the disease is Parkinson disease.